Psychosocial risk, symptom burden, and concerns in families affected by childhood cancer

Purpose The revised Psychosocial Assessment Tool (PATrev) is a common family-level risk-based screening tool for pediatric oncology that has gained support for its ability to predict, at diagnosis, the degree of psychosocial support a family may require throughout the treatment trajectory. However, ongoing screening for symptoms and concerns (e.g., feeling alone, understanding treatment) remains underutilized. Resource limitations necessitate triaging and intervention based on need and risk. Given the widespread use of the PATrev, we sought to explore the association between family psychosocial risk, symptom burden (as measured by the revised Edmonton Symptom Assessment System (ESAS-r)), and concerns (as measured by the Canadian Problem Checklist (CPC)). Methods Families (n = 87) with children <= 18 years of age (M = 11.72, male: 62.1%) on or off treatment for cancer were recruited from the Alberta Children's Hospital. One parent from each family completed the PATrev and the CPC. Participants 8-18 years of age completed the ESAS-r. Results. Risk category (universal/low risk = 67.8%, targeted/intermediate risk = 26.4%, clinical/high risk = 5.7%) predicted symptom burden (F-[2,F- 63.07] = 4.57, p = .014) and concerns (F-[2,F- 82.06] = 16.79, p < .001), such that universal risk was associated with significantly lower symptom burden and fewer concerns. Conclusion Family psychosocial risk is associated with cross-sectionally identified concerns and symptom burden, suggesting that resources might be prioritized for families with the greatest predicted need. Future research should evaluate the predictive validity of the PATrev to identify longitudinal concerns and symptom burden throughout the cancer trajectory.

Automated summary

The study examined the association between family psychosocial risk, symptom burden, and concerns, finding that the level of family risk was associated with symptom burden and concerns, suggesting resources should be prioritized for families with the greatest predicted need. Further research should evaluate the predictive validity of the PATrev in identifying concerns and symptom burden throughout the cancer trajectory.